Literature DB >> 3085263

The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII.

B D Griffin, L R Micklem, M C McCann, K James, D S Pepper.   

Abstract

A panel of 10 murine monoclonal antibodies to procoagulant FVIII has been developed from the fusion of a single spleen. Balb/c mice were injected with a purified preparation of FVIII: Ag, and antibody production in sera and hybrid culture supernatants was monitored using a specific radiometric screening assay. The antibodies all inhibit FVIII clotting activity in normal plasma, and when immobilised on agarose retain their ability to recognise and bind the FVIII procoagulant protein. Studies on protein A-purified immunoglobulins demonstrate a range of properties within the panel of antibodies with regard to species cross-reactivity, clotting inhibition and immunoadsorption. The panel of antibodies has been used to screen heat-treated FVIII concentrates for the occurrence of heat-induced neoantigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085263

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays.

Authors:  V S Hornsey; Y G Waterston; C V Prowse
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

2.  Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine.

Authors:  Gary E Gilbert; Valerie A Novakovic; Jialan Shi; Jan Rasmussen; Steven W Pipe
Journal:  Blood       Date:  2015-07-10       Impact factor: 22.113

3.  Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Authors:  Aaron Peng; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

4.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

5.  Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.

Authors:  J Voorberg; R T de Laaf; P M Koster; J A van Mourik
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

6.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

7.  Development and characterization of lipidic cochleate containing recombinant factor VIII.

Authors:  Razvan D Miclea; Prashant R Varma; Aaron Peng; Sathy V Balu-Iyer
Journal:  Biochim Biophys Acta       Date:  2007-08-19

8.  Detection of intracellular Factor VIII protein in peripheral blood mononuclear cells by flow cytometry.

Authors:  Gouri Shankar Pandey; Sandra C Tseng; Tom E Howard; Zuben E Sauna
Journal:  Biomed Res Int       Date:  2013-02-28       Impact factor: 3.411

9.  Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A.

Authors:  Gouri Shankar Pandey; Chen Yanover; Lisa M Miller-Jenkins; Susan Garfield; Shelley A Cole; Joanne E Curran; Eric K Moses; Natalia Rydz; Vijaya Simhadri; Chava Kimchi-Sarfaty; David Lillicrap; Kevin R Viel; Teresa M Przytycka; Glenn F Pierce; Tom E Howard; Zuben E Sauna
Journal:  Nat Med       Date:  2013-09-15       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.